S.lab (soloways)
Clinical trials sponsored by S.lab (soloways), explained in plain language.
-
New protein therapy shows promise for Tough-to-Treat inflammation
Disease control CompletedThis study tested a protein called GcMAF in 120 people with chronic inflammatory diseases like rheumatoid arthritis that did not respond to standard treatments. The goal was to see if it is safe and can reduce inflammation. The study had two parts: first to find a safe dose, then…
Phase: PHASE1, PHASE2 • Sponsor: S.LAB (SOLOWAYS) • Aim: Disease control
Last updated May 03, 2026 11:30 UTC
-
New injection aims to calm overactive immune cells in arthritis patients
Disease control CompletedThis early-stage study tested a new drug called EF-M2 in 48 adults with moderate-to-severe rheumatoid arthritis. The treatment is designed to reprogram immune cells to reduce inflammation. The main goal was to check safety and side effects, while also looking at how the drug affe…
Phase: PHASE1, PHASE2 • Sponsor: S.LAB (SOLOWAYS) • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC